Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENPORT-NGSK: Etanercept Biosimilar in Etanercept-Naive Rheumatoid Arthritis Using Ultrasound and Clinical/Biomarker Outcomes
jRCTs071200054Completed
- Sponsor
- AYUMI Pharmaceutical Corporation
- Start
- Dec 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of etanercept in rheumatoid arthritis (RA), sponsored by AYUMI Pharmaceutical Corporation. Primary endpoint: Change in Global OMERACT-EULAR Synovitis Score (GLOESS) at 24 weeks. Started Dec 2020; status: completed.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCTs071200054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071200054.